Tovetumab
Based on 1 Customer Validation
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99%
- CAS 番号: 1243266-04-7
- 分子量:145.39 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Human IgG2 kappa
Human
|
PDGFRα |
Tovetumab (10-100 nM, 1-2 h) binds to PDGFRα on H1703 cells (determined by Alexa647-labeled tovetumab)[1].
Tovetumab (0.001-10 nM, 10 min) inhibits ligand-induced phosphorylation of human PDGFRα in MG-63 cells[2].
Tovetumab (0.001-100 nM, 72 h ) inhibits Ligand-induced proliferation of cancer-associated fibroblasts (CAFs) [2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Tovetumab (10 mg/kg, i.p., twice a week) inhibits tumor growth in U118 glioma xenografts[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkey[1]
-
Dosage:0.6, 6.0, and 60 mg/kg
-
Administration:Intravenous injection (i.v.)
-
Result:Induced > 100- fold increases in circulating concentrations of PDGF-AA.
-
Animal Model:U118 glioma xenografts (CB17 SCID)[2]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection (i.p.), twice per week.
-
Result:Produced 101% inhibition of tumor growth.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 kappa
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of SK-N-SH cells labelling PDGFRA/CD14a (red) with Tovetumab (anti-PDGFRA/CD14a) (HY-P99223). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG2 kappa (HY-P99002). Black-Unlabelled control, cells without incubation with primary antibody.
化学情報
-
CAS 番号 1243266-04-7
-
性状 Liquid
-
分子量 145.39 kDa
-
Color Colorless to light yellow
-
SMILES
[Tovetumab]
-
別名
MEDI-575
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Meina Liang, et al. A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy. AAPS J. 2020 Nov 18;23(1):4. [Content Brief]
[2]. Naomi Laing, et al. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer. Mol Pharmacol. 2013 Jun;83(6):1247-56. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Powered by Bioz